Evidence map›Paper›PMID 23913208›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2013

Survival prediction based on inherited gene variation analysis.

Mine S Cicek, Matthew J Maurer, Ellen L Goode

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mine S CicekDepartment of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA.
Matthew J Maurer
Ellen L Goode

Funding

Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyR01CA122443 · NCI · MAYO CLINIC ROCHESTER · PI GOODE, ELLEN L. · 2007 to 2012
$2.7M
Estrogen Bioactivation and Risk of Ovarian CancerR01CA086888 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI SELLERS, THOMAS A · 2002 to 2005
$2.0M
NCI NIH HHS P50 CA136393NCI NIH HHS P50-CA136393- 01A1NCI NIH HHS R01 CA086888NCI NIH HHS R01 CA122443NCI NIH HHS R01-CA122443NCI NIH HHS R01-CA86888
6 · The paper itself

Abstract

There is a significant variation of outcome among ovarian cases. Clinical features such as age, stage, comorbidities, or degree of debulking are known prognostic factors for the disease. However, additional variation remains unexplained, some of which may be due to inherited factors. Here, we describe identification of survival-associated inherited variants in ovarian cancer that can enhance our current prognostic capabilities.

Indexed as

Genetic VariationPrognosisSurvival AnalysisFemaleHumansOvarian NeoplasmsPolymorphism, Single Nucleotide

Identifiers

PMID23913208
PMCPMC4054688

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.